Should cost effectiveness analyses for NICE always consider future unrelated medical costs?

Pieter van Baal, Alec Morton, Werner Brouwer, David Meltzer, Sarah Davis

Research output: Contribution to journalArticle

7 Citations (Scopus)
55 Downloads (Pure)

Abstract

When developing guidance on the use of new technologies within the NHS, NICE recommends the use of cost effectiveness. Specifically, an intervention is deemed cost effective by NICE if ‘its health benefits are greater than the opportunity costs of programmes displaced to fund the new technology, in the context of a fixed NHS budget. In other words, the general consequences for the wider group of patients in the NHS are considered alongside the effects for those patients who may directly benefit from the technology.’ We argue that the technical guidelines for health technology assessment used by NICE should change given this definition of cost effectiveness. The point at issue is the handling of “unrelated future medical costs”.
Original languageEnglish
Article numberj5096
Number of pages5
JournalBritish Medical Journal
Volume359
DOIs
Publication statusPublished - 10 Nov 2017

    Fingerprint

Keywords

  • medical economics
  • medical costs
  • NICE guidance

Cite this